Last updated on April 24, 2014 at 21:24 EDT

Press Statement on Behalf of the Singh Family (The Former Shareholders and Founders of Ranbaxy)

May 23, 2013

GURGAON, India, May 23, 2013 /PRNewswire/ –

On 22 May 2013, Daiichi Sankyo released a press statement where, among other things,
it was stated that it “believes that certain former shareholders of Ranbaxy concealed and
misrepresented critical information concerning the US DOJ and FDA investigations”.

The phrase is an obvious reference to the members and companies of the Singh family
who were shareholders of Ranbaxy.

Daiichi Sankyo’s allegations of concealment and misrepresentation are false and

Daiichi Sankyo purchased the Singh family’s interests in Ranbaxy in 2008 after a long
negotiation process, as is typical of deals of this magnitude, and after conducting full
due diligence on the affairs of Ranbaxy. The negotiations on behalf of Daiichi Sankyo were
led by Mr. Takashi Shoda, Daiichi Sankyo’s current Representative Director and Chairman
and Dr. Tsutomu Une, Executive Director, who is also the current Chairman of Ranbaxy. They
and Daiichi Sankyo were legally advised.

At every step of the way during the negotiation process, Daiichi Sankyo and its
representatives were made aware of the on-going US FDA and DOJ investigations. They were
also given full access to the documents at Ranbaxy pertaining to US FDA and DOJ

Daiichi Sankyo went in to the deal after satisfying itself with its due diligence,
with knowledge of the US DOJ and FDA investigations and with the benefit of legal advice.

At the request of Daiichi Sankyo, Malvinder also agreed to continue at Ranbaxy for a
period of 5 years. Malvinder left Ranbaxy in the middle of 2009. When he left, Dr Tsutomu
Une of Daiichi Sankyo sent him a personal letter of appreciation to thank him for the many
valuable contributions made by him and the Singh family to Ranbaxy. In that letter, Dr Une
said, among other things, as follows:

“On behalf of the board members of Ranbaxy Laboratories Limited, we greatly appreciate
the many valuable contributions made by you and your family to Ranbaxy. Under the
leadership of your family, Ranbaxy has grown from a small pharmaceutical company providing
pharmaceutical products to the people of India in the early years of the last century to
an international generics giant that today has sales of several billion dollars and
customers on every continent and competes internationally with the best in the industry.”

As late as April 2012, Malvinder was invited by Ranbaxy to attend a launch of
Ranbaxy’s new product. Dr Une met Malvinder at that launch. There was no suggestion by Dr
Une or anyone else on behalf of Ranbaxy or Daiichi Sankyo at that time that there was any
concealment or misrepresentation.

The belated suggestion, made years after the fact, that information was concealed from
and/or misrepresented to Daichii Sankyo is false and designed to divert attention away
from Daiichi Sankyo’s own failures to protect itself and its shareholders in the
negotiations and agreement with the Singh family shareholders of Ranbaxy.

It was recently reported that Ranbaxy had entered into a settlement agreement with the
US FDA and DOJ in relation to their investigations and that under that settlement
agreement, Ranbaxy agreed to pay large penalties to the US FDA and DOJ. The decision to
enter into that settlement agreement was made by Ranbaxy and had nothing to do with the
Singh family which was not even consulted by Daiichi Sankyo/Ranbaxy.

        Contact :
        Raghu Kochar
        Mobile : +919811617256

SOURCE The Press Office of the Singh family

Source: PR Newswire